• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Alzamend Neuro Inc.

    2/26/26 5:12:52 PM ET
    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALZN alert in real time by email
    DEFA14A 1 b22626defa14a.htm

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

     

       
    Filed by the Registrant x
    Filed by a Party other than the Registrant ¨
       
    Check the appropriate box:
    ¨ Preliminary Proxy Statement
    ¨ Confidential, For Use of the Commission Only (as Permitted by Rule 14a-6(e)(2))
    ¨ Definitive Proxy Statement
    x Definitive Additional Materials
    ¨ Soliciting Material Pursuant to § 240.14a-12
         

     

    ALZAMEND NEURO, INC.

    (Name of Registrant as Specified in its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):
    x No fee required
    ¨ Fee computed on table below per Exchange Act Rules 14a-6(i) (1) and 0-11. 

     

      (1) Title of each class of securities to which transaction applies:
      (2) Aggregate number of securities to which transaction applies:
      (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
      (4) Proposed maximum aggregate value of transaction:
      (5) Total fee paid:

     

    ¨  Fee paid previously with preliminary materials:
         
    ¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
       (1) Amount Previously Paid:
      (2) Form, Schedule or Registration Statement No.:
      (3) Filing Party:
      (4) Date Filed:

     

     

     

      
     

     

    Step 1:Go to www.envisionreports.com/ALZN.Step 2:Click on Cast Your Vote or Request Materials.Step 3:Follow the instructions on the screen to log in.www.envisionreports.com/ALZNOnlineGo to www.envisionreports.com/ALZN or scan the QR code ? login details are located in the shaded bar below.Shareholder Meeting Notice0492BBImportant Notice Regarding the Availability of Proxy Materials for the Alzamend Neuro, Inc. Stockholder Meeting to be Held on April 17, 2026Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual stockholders' meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important! This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The Stockholder Letter, Proxy Statement, 2025 Stock Incentive Plan and 10-K for Year Ended April 30, 2025 are available at:Obtaining a Copy of the Proxy Materials ? If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before April 7, 2026 to facilitate timely delivery.2NOTEasy Online Access ? View your proxy materials and vote.When you go online, you can also help the environment by consenting to receive electronic delivery of future materials.Step 4:Make your selections as instructed on each screen for your delivery preferences.Step 5:Vote your shares.

     

       

     

    Here's how to order a copy of the proxy materials and select delivery preferences: Current and future delivery requests can be submitted using the options below. If you request an email copy, you will receive an email with a link to the current meeting materials.PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials.? Internet ? Go to www.envisionreports.com/ALZN. Click Cast Your Vote or Request Materials.?Phone ? Call us free of charge at 1-866-641-4276.? Email ? Send an email to [email protected] with "Proxy Materials Alzamend Neuro, Inc." in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials.To facilitate timely delivery, all requests for a paper copy of proxy materials must be received by April 7, 2026.Alzamend Neuro, Inc.'s Annual Meeting of Stockholders will be held on April 17, 2026 at 12:00 p.m. ET, virtually via the Internet at meetnow.global/MYWHGGF. Proposals to be voted on at the meeting are listed below along with the Board of Directors' recommendations.The Board of Directors recommend a vote FOR all the nominees listed and FOR Proposals 2-7:1.Election of Directors:01 - William B. Horne 02 - Milton C. Ault, III 03 - Stephan Jackman04 - Henry C.W. Nisser 05 - Mark Gustafson 06 - Lynne F. McGrath 07- Jeffrey Oram2. To ratify the selection of Haskell & White LLP as the Company's independent registered public accounting firm for the fiscal year ending April 30, 2026.3.To approve, on a non-binding advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement.4. To approve the Company's 2025 Stock Incentive Plan.5. To approve, for purposes of complying with Listing Rule 5635(c) of The Nasdaq Stock Market, LLC, equity issuances to directors and executive officers of the Company.6.To approve an amendment to the Company's Certificate of Incorporation to effect a reverse stock split of the Company's common stock, par value $0.0001 per share by a ratio of not less than one-for-two and not more than one-for-ten at any time prior to April 16, 2027, with the exact ratio to be set at a whole number within this range as determined by the Board of Directors in its sole discretion.7. To approve one or more adjournments of the Annual Meeting to permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the Annual Meeting, there are not sufficient votes to approve one or more of the other proposals before the Annual Meeting.PLEASE NOTE ? YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card. If you wish to attend and vote at the meeting, please bring this notice with you.Stockholder Meeting Notice

     

     

     

     
    Get the next $ALZN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALZN

    DatePrice TargetRatingAnalyst
    10/1/2021$8.00Buy
    Ascendiant Capital Markets
    More analyst ratings

    $ALZN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Horne William B. bought $3,285 worth of shares (3,334 units at $0.99), increasing direct ownership by 13% to 30,000 units (SEC Form 4)

    4 - Alzamend Neuro, Inc. (0001677077) (Issuer)

    3/27/25 7:30:10 AM ET
    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ault Milton C Iii bought $2,969 worth of shares (2,905 units at $1.02) (SEC Form 4)

    4 - Alzamend Neuro, Inc. (0001677077) (Issuer)

    3/25/25 4:30:07 PM ET
    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Katzoff David J bought $5,048 worth of shares (5,000 units at $1.01), increasing direct ownership by 926% to 5,540 units (SEC Form 4)

    4 - Alzamend Neuro, Inc. (0001677077) (Issuer)

    3/24/25 7:30:07 AM ET
    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALZN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alzamend Neuro to Present at the 2025 Military Health System Research Symposium

    Session Topic is the Innovation and Current Directions in Military Suicide Prevention, Research, and ProgramsPresentation Title is Quantitate Differences in Lithium Brain-to-Plasma Exposure in PTSD Subjects Between AL001 and Lithium Carbonate ATLANTA, July 28, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company, focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced it will have a poster presentation at the Military Health System Research Symposium ("MHSRS"), being he

    7/28/25 8:00:00 AM ET
    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs

    During the year ended April 30, 2025, net cash provided by financing activities was $10.4 millionStockholder equity of $4.0 million at April 30, 2025, including $3.9 million of cashIn May 2025, Alzamend dosed the first patient for the healthy human patients for the AL001 "Lithium in Brain" Studies at Massachusetts General HospitalIn June 2025, Alzamend completed the final closing of its $5 million private placement months ahead of schedule ATLANTA, July 23, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"

    7/23/25 8:00:00 AM ET
    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule

    ATLANTA, June 16, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced that it has completed the final closing of its $5 million private placement. As previously reported, on February 28, 2025, Alzamend entered into a Securities Purchase & Exchange Agreement (the "Agreement") with a sophisticated investor (the "Investor"), pursuant to which Alzamend agreed to sell to the Investor up to 500 shares of Series C Conver

    6/16/25 8:00:00 AM ET
    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALZN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ault Milton C Iii sold $3,825 worth of shares (1,851 units at $2.07), closing all direct ownership in the company (SEC Form 4)

    4 - Alzamend Neuro, Inc. (0001677077) (Issuer)

    12/30/25 5:54:03 PM ET
    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Horne William B. sold $7,059 worth of shares (3,333 units at $2.12), closing all direct ownership in the company (SEC Form 4)

    4 - Alzamend Neuro, Inc. (0001677077) (Issuer)

    12/23/25 4:30:14 PM ET
    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mcgrath Lynne Fahey sold $69 worth of shares (30 units at $2.29), decreasing direct ownership by 55% to 25 units (SEC Form 4)

    4 - Alzamend Neuro, Inc. (0001677077) (Issuer)

    10/24/25 4:30:08 PM ET
    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALZN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ascendiant Capital Markets initiated coverage on Alzamend Neuro with a new price target

    Ascendiant Capital Markets initiated coverage of Alzamend Neuro with a rating of Buy and set a new price target of $8.00

    10/1/21 7:11:54 AM ET
    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALZN
    SEC Filings

    View All

    SEC Form DEFA14A filed by Alzamend Neuro Inc.

    DEFA14A - Alzamend Neuro, Inc. (0001677077) (Filer)

    2/26/26 5:12:52 PM ET
    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Alzamend Neuro Inc.

    DEF 14A - Alzamend Neuro, Inc. (0001677077) (Filer)

    2/26/26 5:12:17 PM ET
    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by Alzamend Neuro Inc.

    PRE 14A - Alzamend Neuro, Inc. (0001677077) (Filer)

    2/9/26 4:30:11 PM ET
    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALZN
    Financials

    Live finance-specific insights

    View All

    BitNile Holdings Reports Third Quarter 2022 Financial Results, Including Revenue of $100 Million for the Nine Months Ended September 30, 2022, up 124% from the Prior Year's Nine-Month Period

    BitNile Holdings, Inc. (NYSE:NILE), a diversified holding company ("BitNile" or the "Company"), reported its financial results for the third quarter ended September 30, 2022 on its Form 10-Q filed with the Securities and Exchange Commission. Third quarter 2022 highlights include: Total assets of $610.9 million as of September 30, 2022; Positive working capital of $25.7 million as of September 30, 2022; Cash and cash equivalents of $10.1 million as of September 30, 2022; Revenue from cryptocurrency mining of $3.9 million, compared to $0.3 million in the prior third fiscal quarter; Revenue from the Company's majority owned subsidiary, The Singing Machine Company, Inc. (NASDAQ:MICS)

    11/21/22 7:27:00 PM ET
    $ALZN
    $MICS
    $NILE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Diversified Electronic Products
    Consumer Staples

    BitNile Holdings Reports Second Quarter 2022 Financial Results

    BitNile Holdings, Inc. (NYSE:NILE), a diversified holding company ("BitNile" or the "Company"), reported its financial results for the second quarter ended June 30, 2022 on its Form 10-Q filed with the Securities and Exchange Commission. Second quarter 2022 highlights include: Total assets of $596.3 million as of June 30, 2022; Positive working capital of $51.4 million as of June 30, 2022; Cash and cash equivalents of $24.1 million as of June 30, 2022; Revenue from cryptocurrency mining of $4.0 million, compared to $0.3 million in the prior second fiscal quarter; Revenue from hotel operations of $4.6 million, compared to $0 in the prior second fiscal quarter; Revenue from lendi

    8/23/22 6:30:00 AM ET
    $ALZN
    $NILE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Military/Government/Technical
    Industrials

    BitNile Holdings Reports 2021 Year-End Results

    The Company Grows Revenue by 120% to $52 Million and Ends the Year with $490 Million in Assets BitNile Holdings, Inc. (NYSE:NILE), a diversified holding company ("BitNile" or the "Company") today announced its financial results for the year ended December 31, 2021 contained within its Form 10‑K filed with the Securities and Exchange Commission. Year ended December 31, 2021 highlights: Revenue of $52.4 million, an increase of 120% from $23.9 million in the prior fiscal year; Revenue from lending and trading activities of $16.9 million due to the allocation of capital to Digital Power Lending, LLC ("DP Lending"); Revenue from trading activities during the year ended December 31, 2021

    4/18/22 6:30:00 AM ET
    $ALZN
    $NILE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Military/Government/Technical
    Industrials

    $ALZN
    Leadership Updates

    Live Leadership Updates

    View All

    Alzamend Neuro Appoints Dr. Terri Hunter to Its Scientific Advisory Board

    Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced the appointment of Dr. Terri Hunter, Ph.D., a Technology Transfer Specialist, to its Scientific Advisory Board. During her tenure at the University of South Florida ("USF"), Dr. Hunter was responsible for managing the patent portfolio associated with Alzamend's two product candidates, AL001 and AL002. AL001 is a novel lithium-delivery system; it is a lithium-salicylate-L-proline engineered ionic co-crystal under development as an oral treatment for patients with demen

    4/4/22 8:00:00 AM ET
    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALZN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Alzamend Neuro Inc. (Amendment)

    SC 13D/A - Alzamend Neuro, Inc. (0001677077) (Subject)

    2/2/24 4:38:42 PM ET
    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Alzamend Neuro Inc. (Amendment)

    SC 13D/A - Alzamend Neuro, Inc. (0001677077) (Subject)

    1/25/24 5:21:29 PM ET
    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Alzamend Neuro Inc. (Amendment)

    SC 13D/A - Alzamend Neuro, Inc. (0001677077) (Subject)

    11/15/22 4:30:13 PM ET
    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care